These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35629350)

  • 1. The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.
    Haddad F; Dokmak G; Karaman R
    Life (Basel); 2022 May; 12(5):. PubMed ID: 35629350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study.
    Torri Clerici V; Brambilla L; Politi PL; Viggiani F; Mercurio S; Tonietti S; Ronzoni M; Crisafulli SG; Antozzi C; Tramacere I; Redemagni C; Confalonieri P
    Mult Scler Relat Disord; 2023 Jun; 74():104711. PubMed ID: 37062198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nabiximols oromucosal spray (Sativex
    Garde N; Heibel M
    Drugs Context; 2024; 13():. PubMed ID: 38384931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.
    Häuser W; Welsch P; Klose P; Radbruch L; Fitzcharles MA
    Schmerz; 2019 Oct; 33(5):424-436. PubMed ID: 31073761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis; adverse effects from an oromucosal spray.
    Scully C
    Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
    Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
    J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.
    Guger M; Hatschenberger R; Leutmezer F
    Brain Behav; 2023 Apr; 13(4):e2947. PubMed ID: 36934456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
    Nielsen S; Germanos R; Weier M; Pollard J; Degenhardt L; Hall W; Buckley N; Farrell M
    Curr Neurol Neurosci Rep; 2018 Feb; 18(2):8. PubMed ID: 29442178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary.
    Yadav V; Narayanaswami P
    Clin Ther; 2014 Dec; 36(12):1972-1978. PubMed ID: 25467189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.
    Zettl UK; Rommer P; Hipp P; Patejdl R
    Ther Adv Neurol Disord; 2016 Jan; 9(1):9-30. PubMed ID: 26788128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings.
    Flachenecker P; Saccà F; Vila C
    Case Rep Neurol; 2018; 10(2):169-176. PubMed ID: 30140216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.